Shared Decision Making in Schizophrenia Treatment Video

Although there are now multiple medications available to treat schizophrenia, many gaps still exist as a barrier to treatment success resulting in lower quality of life for this patient population. Shared decision-making and collaborating with patients and caregivers can help address some of these gaps, however this model is complex and takes time.

Presented by the CME Institute of Physicians Postgraduate Press, Inc. and supported by educational grants from Alkermes, Inc. and Sunovion Pharmaceuticals, Inc.

Read the Free Commentary

YOU MAY ALSO BE INTERESTED IN THESE CME INSTITUTE ACTIVITIES

Part 1: A Review of Schizophrenia

Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.

Part 2: Chasing Cognitive and Negative Symptoms:
Unmet Treatment Needs of Patients with Schizophrenia

Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.

Part 3: Impact of Side Effects on Adherence to Schizophrenia Treatment

Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.

Part 4: Balancing Safety and Efficacy with Novel Schizophrenia Treatments

Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.

Save Save